Биомаркеры при метастазах в кости рака молочной железы: современные направления разработки и поиска с целью индивидуализации подходов в лечении

Биомаркеры при метастазах в кости рака молочной железы: современные направления разработки и поиска с целью индивидуализации подходов в лечении

Автор: Большакова С.А., Бычков Ю.М.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры, лекции

Статья в выпуске: 4 т.21, 2021 года.

Бесплатный доступ

Кости являются наиболее частым местом метастазирования большинства солидных опухолей (особенно рака молочной железы и рака предстательной железы). В результате развития костных метастазов могут появиться патологические переломы, компрессия спинного мозга, костные боли, гиперкальциемия. Существуют определенные рекомендации по лечению костных метастазов, например, применение бисфосфонатов и антиRANKL антител (деносумаб), что увеличивает выживаемость пациентов. Однако существует острая необходимость выявления биомаркеров, указывающих на риск костного метастазирования у пациентов. В последнее время интерес сосредоточен на роли генетических регуляторов взаимодействия опухоли и костной микросреды, в частности, микро-РНК в костных метастазах, и их потенциальной роли в качестве циркулирующих маркеров костного метастазирования.

Еще

Костные метастазы, биомаркеры, персонализированная медицина, микро- рнк, костное микроокружение

Короткий адрес: https://sciup.org/149139213

IDR: 149139213

Список литературы Биомаркеры при метастазах в кости рака молочной железы: современные направления разработки и поиска с целью индивидуализации подходов в лечении

  • Agelaki S., Kalylaki A., Markomanolaki H., et al. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. PLoS ONE. 2015. V. 10. No. 6. Article ID e0123683. DOI: 1371/journal.pone.0123683.
  • Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004. V. 116. No. 2. P. 281-297. DOI: 10.1016/s0092-8674(04)00045-5.
  • Blonder J., Xiao Z., Veenstra T.D. Proteomic profiling of differentiating osteoblasts. Expert Rev Proteom. 2006. V. 3. No. 5. 483-496. DOI: 10.1586/14789450.3.5.483.
  • Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumors. J Natl Cancer Inst. 2005. V. 97. No. 1. P. 59-69. DOI: 10.1093/jnci/dji002.
  • Brown J.E., Cook R.J., Lipton A., et al. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat. 2010. V. 123. No. 3. P. 767-779. DOI: 10.1007/s10549-010-0981-1.
  • Brown J.E., Westbrook J.A., Wood S.L. Dedicator of Cytokinesis 4: A Potential Prognostic and Predictive Biomarker Within the Metastatic Spread of Breast Cancer to Bone. Cancer Inform. 2019. V. 18. Article ID 1176935119866842. DOI: 10.1177/1176935119866842.
  • Brown N.K., Ottewell P.D., Evans C.A., Holen I. Osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin Exp Metastasis. 2012. V. 29. No. 8. P. 927-938. DOI: 10.1007/s10585-012-9481-5.
  • Bruderer M., Richards R.G., Alini M., Stoddart M.J. Role and regulation of RUNX2 in osteogenesis. Eur Cell Mater. 2014. V. 28. P.269-286. DOI: 10.22203/ecm.v028a19.
  • Cackowski F.C., Wang Y., Decker J.T., et al. Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer. Prostate 2019. V. 79. No. 14. P.1715-1727. DOI: 10.1002/pros.23896.
  • Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulations of micro-RNA genes miR15 and miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci. USA. 2002. V. 99. No. 24. P. 15524-15529. DOI: 10.1073/pnas.242606799.
  • Christodoulatos G.S., Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World J Clin Oncol. 2014. V. 5. No. 2. P. 71-81. DOI: 10.5306/wjco.v5.i2.71
  • Coleman R., Costa L., Saad F., et al. Consensus on the utility of bone markers in the malignsnt bone disease setting. Crit Rev Oncol Hematol. 2011,80,411-432.
  • Coleman R., Hall A., Albanell J., et al. Effect of MAF amplification on treatment outcomes with adjuvant zolendronic acid in early breast cancer: A secondary analysis of the international, open-label, randomized, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncol. 2017. V. 18. No. 3. P. 1543-1552. DOI: 10.1016/j.critrevonc.2011.02.005.
  • Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006. V. 12. No. 20. Pt. 2. P. 6243s-6249s. DOI: 10.1158/1078-0432.CCR-06-0931.
  • Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001. V. 27. No. 3. P. 165-176. DOI: 10.1053/ctrv.2000.0210.
  • Coleman R.E., Collinson M., Gregory W., et al. Benefits and risks of adjuvant treatment with zolendronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01|04). J Bone Oncol. 2018. V. 13. P. 123-135. DOI: 10.1016/j.jbo.2018.09.008
  • Coleman R.E., Lipton A., Costa L., et al. Possible survival benefits from zolendronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features – An exploratory analysis of placebo-controlled trials. J Bone Oncol. 2013. V. 2. No. 2. P. 70-76. DOI: 10.1016/j.jbo.2013.01.002.
  • Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zolendronic acid. J Clin Oncol. 2005. V. 23. No. 22. P. 4925-4935. DOI: 10.1200/JCO.2005.06.091.
  • Coleman R.E., McCloskey E.V. Bisphosphonates in oncology. Bone. 2011. V. 49. No. 1. P. 71-76. DOI: 10.1016/j.bone.2011.02.003.
  • Croset M., Kan C., Clezardin P. Tumor-derived miRNAs and bone metastasis. Bonekey Rep. 2015. V. 4. Article ID 688. DOI: 10.1038/bonekey.2015.56
  • Croset M., Pantano F., Kan C.W.S., et al. miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes. Cancer Res. 2018. V. 78. No. 18. P. 5259-5273. DOI: 10.1158/0008-5472.CAN-17-3058.
  • De Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008. V. 14. No. 19. P. 6302-6309. DOI: 10.1158/1078-0432.CCR-08-0872.
  • Deng X., Liu Y., Luo M., et al. Circulating miRNA-24 and its target YKL-40 as potential biomarkers in patients with coronary heart disease and type 2 diabetes mellitus. Oncotarget. 2017. V. 21. V. 8. No. 38. P. 63038-63046. DOI: 10.18632/oncotarget.18593.
  • DSP (digital spatial profiling). Адрес доступа https://www.nanostring.com/?s=DSP (дата доступа 15.10.2021).
  • Du W.X., Duan S.F., Chen J.J., et al. Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: A systemic review and meta – analysis. J Cancer Res Ther. 2014. No. 10 (Suppl.). P. C140-C143. DOI: 10.4103/0973-1482.145842.
  • Elfar G.A., Ebrahim M.A., Elsherbiny N.M., Eissa L.A. Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer. Oncol Res. 2017. V. 25. No. 4. P. 641-650. DOI: 10.3727/096504016X14768398678750.
  • Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006. V. 6. No. 4. P. 259-269. DOI: 10.1038/nrc1840.
  • Ford J.A., Jones R., Elders A., et al. Denosumab for the treatment of bone metastases secondary to solid tumors: Systematic review and network meta-analysis. Eur J Cancer. 2013. V. 49. No. 2. P. 416-430. DOI: 10.1016/j.ejca.2012.07.016.
  • Gourdin T., Sonpavde G. Utility of cell-free nucleic acid and circulating tumor cell analysis in prostate cancer. Asian Androl. 2018. V. 20. No. 3. P. 230-237. DOI: 10.4103/aja.aja_1_18.
  • Guise T.A. Breaking down bone: New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev. 2009. V. 23. No. 18. P. 2117-2123. DOI: 10.1101/gad.1854909.
  • Gul G., Sendur M.A., Aksoy S., et al. A comprehensive review of denosumab for bone metastasis in patients with solid tumors. Curr Med Res Opin. 2016. V. 32. No. 1. P. 133-145. DOI: 10.1185/03007995.2015.1105795.
  • Gulyaeva L.F., Kushlinskiy N.E. Regulatory mechanisms of microRNA expression. J Transl Med. 2016. V. 14. No. 1. Article ID 143. DOI: 10.1186/s12967-016-0893-x.
  • Hayashita Y., Osada H., Tatematsu Y., et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005. V. 65. No. 21. P. 9628-9632. DOI: 10.1158/0008-5472.CAN-05-2352.
  • Koopmans N., de Jong I.J., Breeuwsma A.J., van der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol. 2007. V. 178. No. 3. Pt. 1. P. 849-853. DOI: 10.1016/j.juro.2007.05.029.
  • Hoshino A., Costa-Silva B., Shen T.L., et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015. V. 527. P. 329–335. DOI: 10.1038/nature15756.
  • Huntley R., Jensen E., Gopalakrishnan R., Mansky K.C. Bone morphogenetic proteins: Their role in regulating osteoclast differentiation. Bone Rep. 2019. V.10. Article ID 100207. DOI: 10.1016/j.bonr.2019.100207.
  • Ihle C.L., Provers M.D., Straign D.M., et al. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. J Immunother Cancer. 2019. V. 7. No. 1. Article ID 293. DOI: 10.1186/s40425-019-0753-3.
  • Johnson R.W., Merkel A.R., Page J.M., et al. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis. 2014. V. 31. No. 8. P. 945-959. DOI: 10.1007/s10585-014-9682-1.
  • Kong Q.Q., Sun T.W., Dou Q.Y., et al. Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers. 2007. V. 22. No. 3. P. 214-220. DOI: 10.5301/jbm.2008.3777.
  • Krzeszinski J.Y., Wei W., Huynh H., et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2014. V. 512. No. 7515. P. 431-435. DOI: 10.1038/nature13375.
  • Lara P.N. Jr., Ely B., Quinn D.J., et al. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases. Results from SWOG 0421. J Natl Cancer Inst. 2014. V. 106. No. 4. Article ID dju013. DOI: 10.1093/jnci/dju013.
  • Leon S.A., Shapiro B., Sklaroff D.M., Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977 V. 37. No. 3. P. 646-650.
  • LeVasseur N., Clemons M., Hutton B., et al. Bone-targeted therapy use in patients with bone metastases from lung cancer. A systemic review of randomized controlled trials. Cancer Treat Rev. 2016. V. 50. P. 183-193. DOI: 10.1016/j.ctrv.2016.09.013.
  • Li Y., Dong M., Zang X.Y., et al. The emerging role of circulating tumor cells in cancer management. Am J Transl Res. 2020. V. 12. No. 2. P. 332-342.
  • Li Y., Zhang H., Zhao Y., et al. A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ERα-positive breast cancer cells. Oncogene. 2019. V. 38. No. 6. P. 808-821. DOI: 10.1038/s41388-018-0456-0.
  • Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zolendronic acid. Cancer. 2008. V. 113. No. 1. P. 193-201. DOI: 10.1002/cncr.23529.
  • Lipton A., Smith M.R., Fizazi H., et al. Changes in Bone Turnover Marker Level and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clin Cancer Res. 2016. V. 22. No. 23. P. 5713-5721. DOI: 10.1158/1078-0432.CCR-15-3086.
  • Litwin M.S., Tan H.J. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017. V. 317. No. 24. P. 2532-2542. DOI: 10.1001/jama.2017.7248.
  • Liu X., Cao M., Palomares M., et al. Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res. 2018. V. 20. No. 1. P. 1-12. DOI: 10.1186/s13058-018-1059-y.
  • Liu Y., Cao X. Characteristics and Significance of the Pre-metastatic Niche. Cancer Cell. 2016. V. 30. No. 5. P. 668-681. DOI: 10.1016/j.ccell.2016.09.011.
  • Lumachi F., Basso S.M., Camozzi V., et al. Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy. Clin Chim Acta. 2016. V. 460. P. 227-230. DOI: 10.1016/j.cca.2016.07.005.
  • Maheswaran S., Haber D.A. Circulating tumor cells: A window into cancer biology and metastasis. Curr Opin Genet Dev. 2010. V. 20. No. 1. P. 96-99. DOI: 10.1016/j.gde.2009.12.002.
  • Maruotti N., Corrado A., Neve A., Cantatore F.P. Bisphosphonates: Effects on osteoblast. Eur J Clin Pharmacol. 2012. V. 68. No. 7. P. 1013-1018. DOI: 10.1007/s00228-012-1216-7.
  • Muinao T., Deka Boruah H.P., Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019. V. 5. No. 12. Article ID e02826. DOI: 10.1016/j.heliyon.2019.e02826.
  • Myint P.K., Park E.J., Gaowa A., et al. Targeted remodeling of breast cancer and immune cell homing niches by exosomal integrins. Diagn Pathol. 2020. V. 15. No. 1. P. 1-4. DOI: 10.1186/s13000-020-00959-3.
  • Oremek G., Sauer-Eppel H., Klepzig M. Total procollagen type 1 amino-terminal propeptide (total PINP) as a bone metastasis marker in gynecological carcinomas. Anticancer Res. 2007. V. 27. No. 4A. P. 1961-1962.
  • Pang X., Gong K., Zhang X., et al. Osteopontin as multifaceted driver of bone metastasis and drug resistance. Pharmacol Res. 2019. V. 144. P. 235-244. DOI: 10.1016/j.phrs.2019.04.030.
  • Park H.S., Lee A., Chae B.J., et al. Expression of receptor activator of nuclear factor kappa-B as poor prognostic marker in breast cancer. J Surg Oncol. 2014. V. 110. No. 7. P. 807-812. DOI: 10.1002/jso.23737.
  • Pavlovic M., Arnal-Estape A., Rojo F., et al. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. J Natl Cancer Inst. 2015. V. 107. No. 12. Article ID djv256. DOI: 10.1093/jnci/djv256.
  • Pelger R.C., Soerdjbalie-Maikoe V., Hamdy N.A. Strategies for management of prostate cancer-related bone pain. Drugs Aging. 2001. V. 18. No. 12. P. 899-911. DOI: 10.2165/00002512-200118120-00002.
  • Peng Y., Croce C.M. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016. V. 1. Article ID 15004. DOI: 10.1038/sigtrans.2015.4.
  • Pestrin M., Bessi S., Puglisi F., et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat. 2012. V. 134. No. 1. P. 283-289. DOI: 10.1007/s10549-012-2045-1.
  • Reithdorf S., Fritsche H., Muller V., et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of CellSearch system. Clin Cancer Res. 2007. V. 13. No. 3. P. 920-928. DOI: 10.1158/1078-0432.CCR-06-1695.
  • Roelofs A.J., Thompson K., Ebetino F.H., et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des. 2010. V. 16. No. 27. P. 2950-2960. DOI: 10.2174/138161210793563635.
  • Roodman G.D. Mechanisms of bone metastasis. N Engl J Med. 2004. V. 350. No. 8 (Suppl.). P. 1655-1664. DOI: 10.1002/(sici)1097-0142(19971015)80:8+-1546::aid-cncr4-3.3.co;2-r.
  • Sims N.A., Gooi J.H. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 2008. V. 19. No. 5. P. 444-451. DOI: 10.1016/j.semcdb.2008.07.016.
  • Spanjol J., Djordjevic G., Markic D., et al. Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastasis: immunohistochemical study. Coll Antropol. 2010. V. 34. Suppl. 2. 119-125.
  • Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zolendronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010. V. 28. No. 35. P. 5132-5139. DOI: 10.1200/JCO.2010.29.7101.
  • Suda T., Takahashi N., Udagawa N., et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999. V. 20. No. 3. P. 345-357. DOI: 10.1210/edrv.20.3.0367.
  • Summers M.A., McDonald M.M., Croucher P.I. Cancer Cell Dormancy in Metastasis. Cold Spring Harb Perspect Med. 2020. V. 10. No. 4. Article ID a037556. DOI: 10.1101/cshperspect.a037556.
  • Sutherland A., Forsyth A., Cong Y., et al. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation. J Natl Cancer Inst. 2016. V. 108. No. 3. Article ID djv338. DOI: 10.1093/jnci/djv338.
  • Taipaleenmaki H., Farina N.H., Van Wijnene A.J., et al. Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget. 2016. V. 7. No. 48. P. 79032-79046. DOI; 10.18632/oncotarget.12593.
  • Wada N., Fujisaki M., Ishii S., et al. Evaluation of bone metabolic markers in breast cancer with bone metastases. Breast Cancer. 2001. V. 8. No. 2. P. 131-137. DOI: 10.1007/BF02967492.
  • Weidle U.H., Epp A., Birzele F., Brinkmann U. The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs. Cancer Genom Proteom. 2019. V. 5. No. 1. P. 71-81. DOI: 10.21873/cgp.20108.
  • Westbrook J.A., Cairns D.A., Peng J., et al. CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. J Natl Cancer Inst. 2016. V. 108. No. 4. Article ID djv360. DOI: 10.1093/jnci/djv360.
  • Westbrook J.A., Wood S.L., Cairns D.A., et al. Identification and validation of DOCK4 as potential biomarkers for the risk of bone metastasis development in patients with early breast cancer. J Pathol. 2019. V. 247. No. 3. P. 381-391. DOI: 10.1002/path.5197.
  • Westerhuis L.W., Delaere K.P. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer. Eur J Clin Chem Clin Biochem. 1997. V. 35. No. 2. P. 89-94. DOI: 10.1515/cclm.1997.35.2.89.
  • Wiu Z., Lu J. Advanced in treatment of metastatic breast cancer with boe metastasis. Chin Clin Oncol. 2018. V. 7. No. 3. Article ID 31. DOI: 10.21037/cco.2018.06.05.
  • O'Carrigan B., Wong M.H., Willson M.L., et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017. V. 10. No. 10. Article ID CD003474. DOI: 10.1002/14651858.CD003474.pub4.
  • Zhang L., Huang J., Yang N., et al. micro-RNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA. 2006. V. 103. No. 24. P. 9136-9141. DOI: 10.1073/pnas.0508889103.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp